Will Baxter's Novum LVP shipment hold be lifted by December 31, 2026?

Management assumes the hold continues for the full year 2026, and the CEO's language about 'continuing to make progress' and 'update as we go through testing' suggests the correction is still in development rather than near completion. FDA device corrections typically take 12-18 months from identification to resolution, and the hold appears to be in the testing phase as of March 2026. The fact that management cannot even characterize the nature of the correction suggests genuine uncertainty about the timeline.

The language about 'identifying longer-term solutions' and 'corrections to be deployed' (plural) suggests the fix may be more complex than a single field correction. If fundamental design changes are needed, the regulatory pathway includes design verification, validation testing, and potentially a new 510(k) submission — processes that routinely take 12-24 months. With the hold in place since at least late 2025, even an optimistic timeline for a design change would push resolution to late 2026 at earliest, making a full lift before December 31 unlikely.

The cooperative FDA posture (no warning letters, no enforcement actions) is a genuinely positive signal that the issue is being managed constructively. However, insider behavior provides a counterpoint: zero discretionary selling and large grants at lows suggest management expects recovery, but the postponed Investor Day suggests they cannot yet articulate a timeline. A reasonable base case is 30-40% probability of resolution by year-end, weighted toward the lower end given the testing-phase status as of March 2026.

Management's own guidance assumes the hold continues for the full year. When management itself does not expect resolution within the year, that is the strongest signal. The testing-phase language as of Q4 2025 earnings means the fix was not yet validated in February 2026 — leaving only 10 months to complete testing, FDA review, and resumption of shipments. FDA medical device timelines consistently exceed initial estimates.

There is a meaningful scenario where management's full-year hold assumption is conservative — they may be setting a low bar intentionally. The cooperative FDA relationship and the fact that installed units can continue with mitigating actions suggests this is a correctable issue, not a fundamental safety failure. If the correction is a software update or modified instructions for use rather than a hardware change, resolution in H2 2026 is plausible. I estimate roughly 30% probability of the hold being lifted by December 31.

The committee's debate resolution noted 'the hold extending into 2027 remains a realistic downside scenario.' Given that the correction was still in the testing phase in February 2026, even if testing completes by mid-2026, the FDA review and clearance process adds months. The most likely outcome is resolution in H1 2027, not H2 2026. I weight this at roughly 22% for a 2026 resolution.

Management assumes full-year hold. Still in testing phase. But cooperative FDA posture and insider confidence suggest potential for earlier resolution. Roughly 30% chance of resolution by year-end.

FDA device corrections for safety holds typically take longer than expected. Management's conservative assumption of full-year hold is likely realistic given testing-phase status. Low probability of December 2026 resolution.

Balancing management's full-year assumption against the cooperative FDA posture and insider behavior. The insider confidence signal suggests some internal optimism. But the correction is in testing — even a successful test requires FDA review. About 28% probability.